Published in Nature on January 03, 1985
High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol (1987) 43.61
Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell (2012) 5.92
Translating insights from the cancer genome into clinical practice. Nature (2008) 4.37
A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps. Mol Cell Biol (1986) 4.00
Cloning and expression of JE, a gene inducible by platelet-derived growth factor and whose product has cytokine-like properties. Proc Natl Acad Sci U S A (1988) 3.83
A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci U S A (1985) 3.80
Allosteric regulation of the epidermal growth factor receptor kinase. J Cell Biol (1986) 3.78
FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell (2007) 3.46
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene (2007) 3.17
Molecular and biochemical characterization of the human trk proto-oncogene. Mol Cell Biol (1989) 3.10
The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer (2012) 2.79
ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest (2007) 2.78
p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol Cell Biol (1986) 2.52
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell (2014) 2.44
Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc Natl Acad Sci U S A (1988) 2.31
Activation of the receptor kinase domain of the trk oncogene by recombination with two different cellular sequences. EMBO J (1988) 2.19
Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc Natl Acad Sci U S A (2000) 2.19
EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions. EMBO J (1988) 2.15
trkB, a novel tyrosine protein kinase receptor expressed during mouse neural development. EMBO J (1989) 2.14
Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol (2008) 2.01
Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Biochemistry (2006) 1.96
The oncogenic forms of N-ras or H-ras prevent skeletal myoblast differentiation. Mol Cell Biol (1987) 1.95
Involvement of pp60c-src with two major signaling pathways in human breast cancer. Proc Natl Acad Sci U S A (1994) 1.94
Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res (2009) 1.86
Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo. Mol Cell Biol (1988) 1.80
Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res (2007) 1.78
Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J (1993) 1.74
Transforming gene from human stomach cancers and a noncancerous portion of stomach mucosa. Proc Natl Acad Sci U S A (1986) 1.71
Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles. Proc Natl Acad Sci U S A (1986) 1.69
Detection and identification of activated oncogenes in spontaneously occurring benign and malignant hepatocellular tumors of the B6C3F1 mouse. Proc Natl Acad Sci U S A (1986) 1.60
Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet (2002) 1.57
Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci U S A (1986) 1.56
The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity. Mol Cell Biol (1990) 1.52
Stage- and tissue-specific expression of the neu oncogene in rat development. Proc Natl Acad Sci U S A (1987) 1.52
An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer (1988) 1.52
An angiogenic growth factor is expressed in human glioma cells. EMBO J (1987) 1.46
Rat c-raf oncogene activation by a rearrangement that produces a fused protein. Mol Cell Biol (1987) 1.42
A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation. EMBO J (1989) 1.40
ErbB2 is required for muscle spindle and myoblast cell survival. Mol Cell Biol (2002) 1.39
Molecular cloning and characterization of the human dbl proto-oncogene: evidence that its overexpression is sufficient to transform NIH/3T3 cells. EMBO J (1988) 1.39
Kinome-wide Decoding of Network-Attacking Mutations Rewiring Cancer Signaling. Cell (2015) 1.38
Profiling receptor tyrosine kinase activation by using Ab microarrays. Proc Natl Acad Sci U S A (2003) 1.36
Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. EMBO J (1991) 1.33
Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer (1991) 1.33
Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. Proc Natl Acad Sci U S A (1994) 1.31
Distinct isoforms of neuregulin are expressed in mesenchymal and neuronal cells during mouse development. Proc Natl Acad Sci U S A (1994) 1.31
Amplification and overexpression of the met gene in spontaneously transformed NIH3T3 mouse fibroblasts. EMBO J (1986) 1.28
Neural expression and chromosomal mapping of Neu differentiation factor to 8p12-p21. Proc Natl Acad Sci U S A (1993) 1.28
Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation. Proc Natl Acad Sci U S A (1994) 1.24
Transformation by the v-fms oncogene product: role of glycosylational processing and cell surface expression. Mol Cell Biol (1985) 1.22
Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br J Cancer (1993) 1.21
Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int (2014) 1.21
Activated neu oncogene sequences in primary tumors of the peripheral nervous system induced in rats by transplacental exposure to ethylnitrosourea. Proc Natl Acad Sci U S A (1987) 1.21
Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer. Breast Cancer Res (2009) 1.20
The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol (2009) 1.18
Identification and biochemical characterization of p70TRK, product of the human TRK oncogene. Proc Natl Acad Sci U S A (1987) 1.14
Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products. Proc Natl Acad Sci U S A (1988) 1.14
The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer (2003) 1.14
Molecular therapy of breast cancer: progress and future directions. Nat Rev Endocrinol (2010) 1.13
Identification of an activated c-Ki-ras oncogene in rat liver tumors induced by aflatoxin B1. Proc Natl Acad Sci U S A (1986) 1.13
Interaction of antibodies with ErbB receptor extracellular regions. Exp Cell Res (2008) 1.13
Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer (2005) 1.12
Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines. Am J Pathol (1992) 1.09
Bimodal analysis of mammary epithelial cell migration in two dimensions. Ann Biomed Eng (2008) 1.08
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs (2005) 1.08
Molecular cloning and characterization of an activated human c-raf-1 gene. Mol Cell Biol (1987) 1.08
Human cancer and cellular oncogenes. Biochem J (1987) 1.07
Structural domains of the avian erythroblastosis virus erbB protein required for fibroblast transformation: dissection by in-frame insertional mutagenesis. J Virol (1986) 1.07
An activated allele of the c-erbB-2 oncogene impairs kidney and lung function and causes early death of transgenic mice. J Cell Biol (1993) 1.06
Receptor tyrosine kinase transmembrane domains: Function, dimer structure and dimerization energetics. Cell Adh Migr (2010) 1.06
A role for the acetylcholine receptor-inducing protein ARIA in oligodendrocyte development. Proc Natl Acad Sci U S A (1994) 1.03
Inverse regulation of human ERBB2 and epidermal growth factor receptors by tumor necrosis factor alpha. Proc Natl Acad Sci U S A (1993) 1.01
Identification of a novel receptor in Drosophila for both epidermal growth factor and insulin. Proc Natl Acad Sci U S A (1985) 1.01
Pks, a raf-related sequence in humans. Proc Natl Acad Sci U S A (1986) 1.00
Role of proto-oncogene activation in carcinogenesis. Environ Health Perspect (1992) 0.99
Genetic instability favoring transversions associated with ErbB2-induced mammary tumorigenesis. Proc Natl Acad Sci U S A (2002) 0.99
Triplex formation inhibits HER-2/neu transcription in vitro. J Clin Invest (1993) 0.98
Domain deletion in the extracellular portion of the EGF-receptor reduces ligand binding and impairs cell surface expression. Cell Regul (1990) 0.98
HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer. Anticancer Res (2007) 0.96
Induction of a variety of tumors by c-erbB2 and clonal nature of lymphomas even with the mutated gene (Val659----Glu659). EMBO J (1990) 0.96
c-erbB-2 expression in different histological types of invasive breast carcinoma. J Clin Pathol (1991) 0.96
Activation of the neu tyrosine kinase induces the fos/jun transcription factor complex, the glucose transporter and ornithine decarboxylase. J Cell Biol (1989) 0.96
Multiple sequential molecular abnormalities in the evolution of human gliomas. Br J Cancer (1991) 0.96
HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol (2006) 0.95
Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer (1995) 0.95
Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation. Proc Natl Acad Sci U S A (1989) 0.95
ErbB1-4-dependent EGF/neuregulin signals and their cross talk in the central nervous system: pathological implications in schizophrenia and Parkinson's disease. Front Cell Neurosci (2013) 0.95
Clinical Significance of HER-2 Splice Variants in Breast Cancer Progression and Drug Resistance. Int J Cell Biol (2013) 0.93
Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer. Cancer Gene Ther (2010) 0.93
Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study. Breast Cancer Res (2006) 0.93
The induction of apoptosis in human mammary luminal epithelial cells by expression of activated c-neu and its abrogation by glucocorticoids. Br J Cancer (1995) 0.92
Proxy activation of protein ErbB2 by heterologous ligands implies a heterotetrameric mode of receptor tyrosine kinase interaction. Biochem J (1998) 0.92
Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer. ISRN Oncol (2012) 0.92
Testing for HER2 in Breast Cancer: A Continuing Evolution. Patholog Res Int (2010) 0.92
Antigenic and functional characterization of a rat central nervous system-derived cell line immortalized by a retroviral vector. J Cell Biol (1988) 0.92
Challenges in the clinical utility of the serum test for HER2 ECD. Biochim Biophys Acta (2012) 0.91
The G1 phase Cdks regulate the centrosome cycle and mediate oncogene-dependent centrosome amplification. Cell Div (2011) 0.90
Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. Mol Med (2013) 0.90
A subgroup of patients with chronic pancreatitis overexpress the c-erb B-2 protooncogene. Ann Surg (1994) 0.89
Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. Br J Cancer (2003) 0.89
The hallmarks of cancer. Cell (2000) 113.05
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature (1983) 19.76
Tumor spectrum analysis in p53-mutant mice. Curr Biol (1994) 16.60
Creation of human tumour cells with defined genetic elements. Nature (1999) 16.47
hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell (2001) 15.97
A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature (1986) 13.96
Mechanism of activation of a human oncogene. Nature (1982) 12.09
Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev (2001) 11.25
Effects of an Rb mutation in the mouse. Nature (1992) 11.06
Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature (1988) 10.98
A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A (1995) 10.25
hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell (1997) 8.74
Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell (1992) 7.61
Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature (1993) 7.20
Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature (1985) 7.07
Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell (1986) 7.06
Multiple protein-binding sites in the 5'-flanking region regulate c-fos expression. Mol Cell Biol (1986) 7.06
Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell (1982) 6.93
Cellular oncogenes and multistep carcinogenesis. Science (1983) 6.52
Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature (1982) 6.09
Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell (1995) 6.08
Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci U S A (1985) 5.93
The integrated genome of murine leukemia virus. Cell (1978) 5.84
The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature (1986) 5.77
Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. Proc Natl Acad Sci U S A (1979) 5.32
Physical interaction of the retinoblastoma protein with human D cyclins. Cell (1993) 5.31
Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol (2000) 5.28
Acrylamide gel electrophoresis of HeLa cell nucleolar RNA. Proc Natl Acad Sci U S A (1967) 5.06
Spk1/Rad53 is regulated by Mec1-dependent protein phosphorylation in DNA replication and damage checkpoint pathways. Genes Dev (1996) 4.98
Small molecular weight monodisperse nuclear RNA. J Mol Biol (1968) 4.96
Inhibition of telomerase limits the growth of human cancer cells. Nat Med (1999) 4.96
The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta (1994) 4.92
Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature (1981) 4.72
Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase. Cell (1992) 4.68
Rad53 FHA domain associated with phosphorylated Rad9 in the DNA damage checkpoint. Science (1998) 4.59
Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol (1998) 4.54
DNA sequences homologous to vertebrate oncogenes are conserved in Drosophila melanogaster. Proc Natl Acad Sci U S A (1981) 4.17
Suppression of intestinal neoplasia by DNA hypomethylation. Cell (1995) 4.16
Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc Natl Acad Sci U S A (1998) 4.11
Isolation and characterization of simian virus 40 ribonucleic acid. J Virol (1972) 4.09
Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci U S A (1990) 4.06
Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature (1996) 4.05
Restriction endonuclease cleavage of linear and closed circular murine leukemia viral DNAs: discovery of a smaller circular form. Cell (1979) 4.04
Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet (1994) 3.97
A defined subgenomic fragment of in vitro synthesized Moloney sarcoma virus DNA can induce cell transformation upon transfection. Cell (1979) 3.74
Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. Proc Natl Acad Sci U S A (1987) 3.72
Identification of DNA fragments carrying ecotropic proviruses of AKR mice. Proc Natl Acad Sci U S A (1979) 3.64
The action of oncogenes in the cytoplasm and nucleus. Science (1985) 3.62
Shared role of the pRB-related p130 and p107 proteins in limb development. Genes Dev (1996) 3.61
Phenotype of mice lacking functional Deleted in colorectal cancer (Dcc) gene. Nature (1997) 3.57
Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res (2001) 3.48
Cell cycle-specific association of E2F with the p130 E1A-binding protein. Genes Dev (1993) 3.41
Point mutational inactivation of the retinoblastoma antioncogene. Science (1989) 3.37
Specificity within the EGF family/ErbB receptor family signaling network. Bioessays (1998) 3.37
Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev (2000) 3.30
A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature (1989) 3.27
Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J Biol Chem (1995) 3.27
Characterization of a human colon/lung carcinoma oncogene. Nature (1983) 3.26
The lck tyrosine protein kinase interacts with the cytoplasmic tail of the CD4 glycoprotein through its unique amino-terminal domain. Cell (1989) 3.24
A paracrine role for the epithelial progesterone receptor in mammary gland development. Proc Natl Acad Sci U S A (1998) 3.23
Antigen- and receptor-driven regulatory mechanisms. IV. Idiotype-bearing I-J+ suppressor T cell factors induce second-order suppressor T cells which express anti-idiotypic receptors. J Exp Med (1980) 3.21
Proposal for naming host cell-derived inserts in retrovirus genomes. J Virol (1981) 3.18
Altered cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts. Mol Cell Biol (1996) 3.15
Infectious viral DNA of murine leukemia virus. Proc Natl Acad Sci U S A (1975) 3.09
The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol (1995) 3.09
Growth suppression by p16ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci U S A (1995) 3.08
Murine leukemia virus: detection of unintegrated double-stranded DNA forms of the provirus. Proc Natl Acad Sci U S A (1975) 3.07
The pathway to signal achievement. Nature (1993) 3.03
Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1. J Biol Chem (1996) 3.01
The HL-60 transforming sequence: a ras oncogene coexisting with altered myc genes in hematopoietic tumors. Cell (1983) 3.00
E2F-4 and E2F-5, two members of the E2F family, are expressed in the early phases of the cell cycle. Proc Natl Acad Sci U S A (1995) 2.99
Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc Natl Acad Sci U S A (1997) 2.97
Structure of the intermediates leading to the integrated provirus. Biochim Biophys Acta (1977) 2.96
Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene (1996) 2.96
Association between GTPase activators for Rho and Ras families. Nature (1992) 2.92
Molecular cloning of cDNAs encoding the GAP-associated protein p190: implications for a signaling pathway from ras to the nucleus. Cell (1992) 2.90
Expression cloning and characterization of the TGF-beta type III receptor. Cell (1991) 2.89
G1/S phosphorylation of the retinoblastoma protein is associated with an altered affinity for the nuclear compartment. Cell (1991) 2.87
Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci U S A (1994) 2.87
Association of Cdk-activating kinase subunits with transcription factor TFIIH. Nature (1995) 2.87
Behavior of myc and ras oncogenes in transformation of rat embryo fibroblasts. Mol Cell Biol (1986) 2.86
The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science (1985) 2.80
Three different human tumor cell lines contain different oncogenes. Cell (1981) 2.77
Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell (1985) 2.75
The catalytic subunit of yeast telomerase. Proc Natl Acad Sci U S A (1997) 2.72
Processing of 45 s nucleolar RNA. J Mol Biol (1970) 2.60
Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J (1988) 2.59
Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell (1990) 2.58
Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences. EMBO J (1994) 2.57
Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet (1998) 2.56
Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene (1998) 2.56
Rescue of cyclin D1 deficiency by knockin cyclin E. Cell (1999) 2.54
Generation of novel, biologically active Harvey sarcoma viruses via apparent illegitimate recombination. J Virol (1981) 2.53
p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol Cell Biol (1986) 2.52